Apixaban
Apixaban is an oral anticoagulant medication belonging to the direct factor Xa inhibitor class, used to prevent and treat blood clots. It is indicated for reducing the risk of stroke and systemic embolism in eligible patients with non-valvular atrial fibrillation, treating deep vein thrombosis (DVT) and pulmonary embolism (PE), preventing recurrent venous thromboembolism, and preventing DVT following certain hip or knee replacement surgeries. Apixaban works by selectively inhibiting factor Xa, an essential enzyme in the blood coagulation cascade, thereby reducing thrombin generation and clot formation. It is available as oral tablets, with dosage determined by the indication and individual patient factors, including kidney function, age, body weight, and interacting medications. The most common and clinically significant adverse effect is bleeding, which may range from minor bruising to serious or life-threatening haemorrhage. Treatment requires appropriate medical supervision, careful assessment of bleeding risk, and review of drug interactions. Apixaban should not be discontinued without medical advice because premature interruption can increase the risk of thrombotic events.
Apixaban was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Apixaban, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Apixaban from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Apixaban, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
